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Cardiovascular drugs are a common cause of poisoning, and toxic bradycardias can be refractory to standard ACLS protocols. It
is important to consider appropriate antidotes and adjunctive therapies in the care of the poisoned patient in order to maximize
outcomes. While rigorous studies are lacking in regards to treatment of toxic bradycardias, there are small studies and case reports
to help guide clinicians’ choices in caring for the poisoned patient. Antidotes, pressor support, and extracorporeal therapy are
some of the treatment options for the care of these patients. It is important to make informed therapeutic decisions with an
understanding of the available evidence, and consultation with a toxicologist and/or regional Poison Control Center should be
considered early in the course of treatment.
1.Background
Nearly2000poisoned patients areseenperdayinEmergency
Departments across the United States, and unintentional
poisoning is a signiﬁcant cause of mortality even surpassing
motor vehicle accidents as a cause of death in people aged
35–54 [1]. Cardiovascular drugs rank second only behind
analgesicsastheleadingcauseoffatalityinpoisonedpatients.
Polypharmacy, intentional or unintentional ingestions, and
toxic exposures should be entertained in the diﬀerential
diagnosis of the bradycardic critically ill patient. Consid-
eration and recognition of poisoning may shed light onto
altered physiologic responses that may be refractory to
traditional therapies. Standard resuscitation algorithms are
often insuﬃcient, and it is important to consider appropriate
antidotes and adjunctive therapies when caring for the poi-
soned patient. Additionally, consultation with a toxicologist
or poison control center is recommended to assist in caring
for the poisoned patient.
Toxic bradycardias are often refractory to standard ACLS
protocols due to toxin eﬀects on cardiac and vascular
receptors and cellular physiology. Recognition of a toxic eti-
ology for compromised circulation in the setting of brady-
cardia is crucial in tailoring appropriate therapy. Beta
blockers, calcium channel blockers, and cardiac glycosides
(digoxin) represent the classes of medication most described
in association with fatality due to drug exposure according
to the American Association of Poison Control Centers.
This discussion will also brieﬂy cover clonidine and acetyl-
cholinesterase inhibitors, such as organophosphates and
carbamates, because both have therapeutic consideration
outside of standard supportive care.
This paper discusses common treatment considerations
that apply to the critically ill poisoned patient with a
toxic bradycardia. The goal is to focus on the evidence
or lack of evidence for speciﬁc therapies but not to
provide an exhaustive review of each toxin and/or med-
ication. A MEDLINE search was conducted using the
following search terms: Beta blocker OR beta antagonist,
calcium channel blocker OR calcium antagonist, clonidine,
digoxin, acetylcholinesterase inhibitor OR organophosphate
OR carbamate; overdose OR toxicity; insulin, glucagon,
calcium chloride OR calcium gluconate, lipid emulsion
OR intralipid, vasopressors, epinephrine, norepinephrine,
dopamine, vasopressin, atropine, Pralidoxime OR 2-PAM,
naloxone, Digibind OR DigiFab, balloon pump, CVVHD,
ECMO, and cardiopulmonary bypass. Case reports, case
series, and human and animal studies pertinent to the
etiologiesofbradycardiadiscussedhereinafterwereincluded.
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and cases with multiple substances ingested were excluded.
Major toxicology textbooks were also reviewed for expert
consensus.
Whilethispaperhighlightscurrentliterature,itisimpor-
tant to remember that toxicology research is often limited
to case series, case reports, and animal studies with few
controlled trials. Many treatment guidelines are based on
expert consensus, and further research is encouraged to
strengthen an evidence-based approach to the care of the
poisoned patient.
2.Decontamination
Decontamination is a complex and controversial issue that
is an important consideration in every poisoned patient. A
complete discussion of decontamination is beyond the scope
of this review but key points related to decontamination of
the patient with toxic bradycardia will be highlighted. Stan-
dard gastrointestinal decontamination techniques include
orogastric lavage (OGL), activated charcoal (AC), and whole
bowel irrigation (WBI). Despite popular application of these
techniques for poisoned patients in the past, none of these
therapies has proven to have a signiﬁcant impact on clinical
outcomes and, thus, their use has been largely limited to
speciﬁc situations. Because ingestion of cardioactive drugs
often is associated with signiﬁcant morbidity and mortality,
early aggressive decontamination may be of relative beneﬁt.
For patients who present within 1 hour of ingestion of
a potentially serious toxin, AC or OGL can be considered
if airway protection can be ensured [2, 3]. However, many
cardiovascular drugs come in formulations that may be too
large to pass through the holes of a lavage tube and this
should be considered when deciding to perform OGL. WBI
may be considered for patients who present with ingestion
of medications that are sustained release or extended release
preparations. Often calcium channel blockers and beta
blockers come in SR or XL forms that may be amenable to
WBI [4].
3. Therapy
3.1. Beta Blockers and Calcium Channel Blockers. Calcium
channel blockers and beta blockers are separate categories
of medication each with their own distinct mechanism of
action, but it is very diﬃcult to distinguish the two classes of
medication in a patient who has overdosed. In the absence
of a good history or pill bottle evidence, a clinician may
have to treat a patient based on the assumption that the
oﬀending agent is either a calcium channel blocker or beta
blocker. Common ﬁndings include myocardial depression
and peripheral vasodilation. AV conduction abnormalities,
idioventricular rhythms, and heart block may be seen on
EKG. Most calcium channel blockers and the lipophilic beta
blockers undergo hepatic metabolism and liver failure can
result in accumulation, while the water soluble forms can
easily accumulate in patients with renal failure. Toxicity can
be profound when the two classes of agents are coingested.
Fortunately the treatment of both classes of medication
Table 1: Digoxin antibody dosing recommendations.
Known amount
ingested
Amount of digoxin ingested (mg)/0.5 =
number of vials
Known serum level ((Serum digoxin (ng/mL) × weight (kg)))/
100= number of vials
Empiric dosing Acute overdose = 10 vials
Chronic overdose = 5v i a l s
overlaps and that is why they are discussed together. Special
note should be given to the beta blockers with membrane
stabilizing eﬀects and potassium channel blockade, as ther-
apy needs to be tailored in consideration of these additional
mechanisms of toxicity.
While there is a paucity of literature that directly
addresses the eﬃcacy of speciﬁc antidotes in the setting of
beta blocker and calcium blocker toxicity, there are some
small studies and anecdotal evidence to guide therapy in
patients who do not respond to standard ACLS protocols.
The International Liaison Committee on Resuscitation in
conjunction with the American Heart Association recently
published novel guidelines on the resuscitation of poisoned
patients [5].
There are numerous case studies showing improvement
of hemodynamic parameters without signiﬁcant adverse
eﬀects for beta-blocker-poisoned patients treated with gluc-
agon [6–15]. Glucagon bypasses the beta receptor to initiate
the same intracellular cascade as a beta agonist. A bolus
dose of 5–10mg followed by an infusion of 1–5mg/hr
(0.15mg/kg) is recommended. It is important to treat the
patient with an antiemetic prior to glucagon infusion, as
nausea and vomiting are a common side eﬀect.
High-dose insulin-euglycemic therapy (HIE) also shows
promiseinbothbeta-blocker-andcalcium-channel-blocker-
induced hemodynamic compromise based on case reports
and animal data [16–33]. The exact mechanism has yet
to be elucidated but is believed to be related to improved
metabolic function of the cell. While hypoglycemia is a
concern, proper monitoring and glucose supplementation
will prevent iatrogenic injury. Regular insulin can be given as
an initial 0.5–2.0 unit bolus followed by 0.5 units per hour
with glucose supplementation and electrolyte monitoring
with special attention given to potassium.
Calcium infusion, while long considered the mainstay
of therapy in calcium channel blocker overdose, only has
anecdotal evidence to support its use and there is no clear
consensus on appropriate dosing [34, 35]. An appropriate
starting dose is 1–3gm, and higher doses have been used
with success in refractory cases. Calcium gluconate (10%) is
preferred when given through a peripheral line and proper
dosing is 3 times the equivalent volume of calcium chloride
(10%) [36].
Lipid emulsion therapy is a novel therapy originally
directed at anesthetic toxicity but there are animal studies
and case reports in beta blocker and calcium channel blocker
overdose that indicate a potential beneﬁt [37–40].
Bradycardia with decreased perfusion caused by digoxin
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Table 2: Literature on vasopressor use in toxic bradycardia.
Study Summary
Kerns, W., 2nd, et al., Insulin improves survival in a canine model of
acute beta-blocker toxicity. Annals of Emergency Medicine, 1997.
29(6): p. 748–57.
Survival better for animals treated with insulin compared to
those treated with glucagon or epinephrine.
Toet, A.E., et al., Reduced survival after isoprenaline/dopamine in
d,l-propranolol intoxicated rats. Human and Experimental Toxicology,
1996. 15(2):120–8.
No improvement in hemodynamic variables with
isoproterenol. Addition of dopamine resulted in decreased
MAP and survival time.
Toet, A.E., et al., Experimental study of the detrimental eﬀect of
dopamine/glucagon combination in d,l-propranolol intoxication.
Human and Experimental Toxicology, 1996. 15(5): 411–21.
No improvement of survival time with dopamine/glucagon
but some improvement in hemodynamic variables.
Holger, J.S., et al., A comparison of vasopressin and glucagon in
beta-blocker induced toxicity. Clinical Toxicology: The Oﬃcial Journal
of the American Academy of Clinical Toxicology and European
Association of Poisons Centres and Clinical Toxicologists, 2006. 44(1):
45–51.
Vasopressin resulted in higher MAP/SBP but no diﬀerence in
survival compared to glucagon in porcine model.
Holger, J.S., et al., Insulin versus vasopressin and epinephrine to treat
beta-blocker toxicity. Clinical Toxicology: The Oﬃcial Journal of the
American Academy of Clinical Toxicology and European Association
of Poisons Centres and Clinical Toxicologists, 2007. 45(4): 396–401.
Increased SVR with vasopressin/epinephrine but decreased
survival when compared to insulin in porcine model.
Kanagarajan, K., et al., The use of vasopressin in the setting of
recalcitrant hypotension due to calcium channel blocker overdose.
Clinical Toxicology: The Oﬃcial Journal of the American Academy of
Clinical Toxicology and European Association of Poisons Centres and
Clinical Toxicologists, 2007. 45(1): p. 56–9.
Successful use of vasopressin in patient refractory to other
therapies.
Kline, J.A., E. Leonova, and R.M. Raymond, Beneﬁcial myocardial
metabolic eﬀects of insulin during verapamil toxicity in the
anesthetized canine. Critical Care Medicine, 1995. 23(7): p. 1251–63.
Insulin resulted in improved hemodynamic variables
compared to epinephrine, calcium chloride, or glucagon.
Stone, C.K., et al., Glucagon and phenylephrine combination versus
glucagon alone in experimental verapamil overdose. [see comment].
Academic Emergency Medicine, 1996. 3(2): p. 120–5.
Decreased survival when phenylephrine combined with
glucagon.
Barry, J.D., et al., Vasopressin treatment of verapamil toxicity in the
porcine model. J Med Toxicol, 2005. 1(1): p. 3–10. Decreased survival with vasopressin.
Sztajnkrycer, M.D., et al., Use of vasopressin in a canine model of
severe verapamil poisoning: a preliminary descriptive study. Academic
Emergency Medicine, 2004. 11(12): p. 1253–61.
Decreased cardiac index and no improvement in MAP.
Anderson FJ, Hart GR, Crumpler CP, Lerman MJ: Clonidine overdose:
Report of six cases and review of the literature. Ann Emerg Med 1981;
10:107–112.
Successful use of dopamine for improved blood pressure.
should be treated with antidigoxin immune fragments.
Dosing can be delivered empirically, based on measured
digoxin levels, or based on known ingestion amounts. See
Table 1 for dosing guidelines. Hyperkalemia is an ominous
ﬁnding in digoxin toxicity and serves as an indicator of
toxicity. Avoidance of calcium salts in the setting of digoxin
poisoning has been a long-standing axiom. This mantra is
based on the infamous “stone heart” phenomena described
indogsin1939[41].However,thereisliteraturetorefutethis
consequence when calcium was given to digoxin-poisoned
swine [42]. Despite this evidence, there is no role for calcium
in the setting of hyperkalemia due to digoxin poisoning,
but this study can provide reassurance for the clinician who
wantstogivecalciumincasesofundiﬀerentiatedbradycardia
that is unlikely but not certain to be digoxin toxicity.
Evidence shows that treatment of the hyperkalemia does
not improve outcomes, and it is more important to pursue
antibody treatment of the underlying digoxin toxicity [43].
Although part of standard ACLS protocols, cardiac pacing
can be detrimental in digoxin-poisoned patients. Higher
morbidity and mortality has been described in digoxin-
poisoned patients who underwent pacing compared with
those who received immunotherapy alone [44]. Class Ib
antidysrhythmics such as phenytoin or lidocaine can be
used as temporizing therapy until immune fragments are
available. Phenytoin has been shown to improve digitalis-
induced AV nodal conduction blockade [45, 46].
Clonidine may also cause hemodynamically signiﬁcant
bradycardia. Most cases of clonidine overdose respond well
to supportive care; however refractory cases may occur.
There is mixed success reported in the literature regarding
the use of naloxone for clonidine-induced bradycardia and
hypotension, even when used at higher doses [47–50].
Aggressive supportive care and standard ACLS therapy with
ﬂuid resuscitation, atropine, and pressor support is usually
adequate for clonidine poisoned patients. Yohimbe can4 Emergency Medicine International
be considered as an alpha-2 antagonist but the beneﬁt is
theoretical and delivery is limited to nonpharmaceutical
g r a d eo r a lp r e p a r a t i o n s[ 51].
For bradycardia caused by acetylcholinesterase inhib-
itors, atropine is the mainstay of therapy, not only for the
bradycardia but more importantly to treat the copious
bronchial secretions due to cholinergic excess. A useful
starting dose is 2mg but gram-quantity doses may be
required [52, 53]. Early mobilization of pharmacy resources
is necessary to ensure that adequate stocks of atropine are
available. Concurrent airway management is paramount,
and endotracheal intubation with positive pressure venti-
lation should be considered early. Use of neuromuscular
blocking agents that are metabolized by cholinesterase such
as succinylcholine may result in prolonged paralysis and
alternate agents should be utilized [54]. Pralidoxime should
be given as an adjunct to atropine in patients exposed to
organophosphates to prevent aging and to provide relief
from both muscarinic and nicotinic symptoms [55, 56]. The
initial dose is 1-2 grams IV over 10–15 minutes followed
by an infusion of 250–500mg/hour. Pralidoxime use in the
setting of carbamates is controversial, and consultation with
a toxicologist is recommended [57].
3.2. Pressor Support. Despite ACLS recommendations to
consider pressor therapy in poisoned patients with hemo-
dynamic compromise, there is no clear consensus regarding
the best choice of medication for hemodynamic support.
There are numerous studies exploring various pressors and
combinations in the setting of many diﬀerent toxins. There
are serious limitations in all the available literature and
no agent can be considered superior. Table 2 highlights the
available studies related to vasopressor therapy in the toxic
agents discussed previously. Attention to cardiac output and
peripheral vascular resistance can help guide the choice of
pharmacologic agents for hemodynamic support.
3.3. Extracorporeal Therapy. While a mainstay of ACLS pro-
tocols, cardiac pacing may have limited utility in the patient
with toxic bradycardia due to beta blockers or calcium chan-
nel blockers and may even be detrimental in patient with
digoxin toxicity as noted previously. Pacing may improve
heartrate,butevenifthereiselectricalcapture,improvement
in hemodynamic parameters may not be seen [58–62]. There
are a variety of other therapeutic options that are mentioned
in the literature without rigorous study to support or refute
their eﬃcacy [62–67]. Consideration of nonpharmaceutical
therapies such as CVVHD, intra-aortic balloon pumps, and
ECMO should be considered on a case by case basis utilizing
the expertise of the appropriate consultant.
4. Conclusion
ACLS protocols may be of limited utility when treating
poisoned patients with toxic bradycardia. Use of speciﬁc
antidotes/adjunctive therapies may prove helpful and should
beconsideredearlyinthecourseoftreatmentinconsultation
withamedicaltoxicologistorregionalpoisoncontrolcenter.
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